![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 46, 35799-35806, November 17, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene in the Pancreatic
-Cell*
§,
,
,
,
,
, and
**
From the
Molecular Nutrition Unit, Department of
Nutrition, University of Montreal and the Centre Hospitalier de
l'Université de Montreal and Institut du Cancer, Montreal,
Quebec H2L 4M1, Canada, the ¶ Touchstone Center for
Diabetes Research, Department of Biochemistry and Internal Medicine,
University of Texas Southwestern Medical Center, Dallas, Texas 75235, and the
Department of Medical Biochemistry, Centre Médical
Universitaire, University of Geneva, Geneva 1211, Switzerland
Received for publication, July 7, 2000, and in revised form, August 11, 2000
| |
ABSTRACT |
|---|
|
|
|---|
To better understand the action of glucose on
fatty acid metabolism in the Excessive carbohydrate and fat intake is thought to play an
important role in the etiology of adipogenic diabetes (1-3). For
instance, caloric restriction of obese prediabetic Zucker Diabetic
Fatty (ZDF)1
(fa/fa) rats prevents diabetes and the loss of
glucose-stimulated secretion in this animal model of adipogenic
non-insulin-dependent diabetes mellitus (4). The
mechanisms causing Because both elevated glucose and FFA probably contribute to the
progressive demise of the Peroxisome proliferator-activated receptors (PPARs) are fatty acid
sensors, which transduce nutritional stimuli into changes in gene
expression. The PPAR Because both excessive glucose and fatty acids may be implicated in the
progressive Materials--
Pancreatic islets were isolated using collagenase
(type IV) from Worthington (Lakewood, NJ) and Ficoll DL-400 from
Sigma. Reverse transcriptase was purchased from Rote Molecular
Biochemical (Laval, Quebec, Canada), Taq polymerase was from
Life Technologies, Inc., and Pd(N)6 hexamer was from
Amersham Pharmacia Biotech. Protran nitrocellulose membranes for
protein analysis were from Schleicher & Schuell (Dassel,
Germany), and the bicinchoninic acid protein assay was from Pierce. The
enhanced chemiluminescence detection kit for Western blot (ECL) and
T4-kinase were from Amersham Pharmacia Biotech. The horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulin antibody and zeta
probe membrane were obtained from Bio-Rad.
Pancreatic Islet Isolation and Cell Culture--
Islets were
isolated from Wistar rats (Charles River, St.-Constant, Quebec, Canada)
weighing ~200 g by collagenase digestion of the total pancreas and
subsequent separation on discontinuous Ficoll DL-400 gradients as
described previously by Gotoh et al. (30). Islets and INS-1
(31) and INS(832/13) (32) cells were kept in culture at 37 °C in a
humidified atmosphere containing 5% CO2. At the end of the
isolation step, islets were maintained at 15-20 islets/ml in regular
RPMI 1640 medium containing 11 mM glucose supplemented with
10% fetal calf serum, 10 mM Hepes (pH 7.4), 1 mM sodium pyruvate, and 50 µM
RNA Extraction and Reverse Transcriptase-PCR Analysis--
Total
RNA was extracted from 50 islets and INS(832/13) cells by the
guanidinium thiocyanate/phenol/chloroform extraction method (33) using
20 µg of yeast tRNA as a carrier for islet RNA. First strand cDNA
was generated from either the total amount of islet RNA or from 5 µg
of INS(832/13) cell RNA in 50 µl (final volume) of a buffer
containing the oligonucleotides Pd(N)6 (34). 3 µl (PPAR Nuclear Extract Preparation and Electrophoretic Mobility Shift
Assays--
Nuclear extracts were prepared from INS(832/13) cells as
described (36). Briefly, cells were collected, washed twice with cold
phosphate-buffered saline, and lysed in 500 µl of ice-cold buffer A
(10 mM Hepes (pH 7.8), 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 2 mM phenylmethylsulfonyl fluoride).
After a 15-min incubation on ice, Nonidet P-40 (0.5% final
concentration) was added, samples were gently vortexed, and nuclei from
lysed cells were centrifuged at 1000 rpm for 2 min. Nuclei were washed twice with buffer A without Nonidet P-40. Nuclei were then lysed in
buffer A containing 26% glycerol, 0.2 mM EDTA, and 450 mM NaCl. After a 15-min incubation on ice, nuclear extracts
were centrifuged for 2 min at 1000 rpm. Aliquots (50 µl) of the
supernatants were frozen at Western Blot Analysis--
The proteins obtained from nuclear
extracts were analyzed on 10% SDS-containing polyacrylamide gels.
Proteins were then transferred to nitrocellulose filters, and PPAR Malonyl-CoA and Insulin Secretion Measurements--
Following
cell culture for 3 days in 21-cm2 Petri dishes at 5 or 25 mM glucose with or without 0.4 mM oleate bound
to bovine serum albumin (0.5%), INS-1 cells were washed with
phosphate-buffered saline and preincubated at 37 °C for 30 min in
Krebs-Ringer bicarbonate buffer (KRBB) with 25 mM Hepes (pH
7.4) (9), at 5 mM glucose, containing 0.07% BSA (Fraction
V, Sigma). Cells were then incubated for 30 min in fresh KRBB-Hepes at
5 or 25 mM glucose. Incubation media were discarded,
and malonyl-CoA was extracted from cells with 10% trichloroacetic
acid. After centrifugation of precipitated proteins, cell extracts were
brought to pH 5-6 by successive ether extractions. Samples were
lyophilized and stored at Fatty Acid Metabolism and Triglyceride Measurements--
Fatty
acid oxidation was measured in INS-1 cells cultured in
21-cm2 Petri dishes. Following a preexposure for 3 days at
5 or 25 mM glucose in the absence or presence of 0.4 mM oleate, cells were washed with phosphate-buffered saline
and preincubated at 37 °C for 30 min in KRBB-Hepes (pH 7.4) medium,
at 5 mM glucose, containing 0.07% BSA. Cells were then
incubated for 1 h at 37 °C in 5 ml of fresh KRBB-Hepes at 5 or
25 mM glucose in the presence of 0.1 mM
palmitate, 0.5% defatted BSA, 1 mM carnitine, and 0.11 µCi of [1-14C]palmitate (55 mCi/mmol) (Amersham
Pharmacia Biotech). At the end of the incubations media were
collected and transferred to 25-ml Erlenmeyer flasks covered with septa
caps. Media were acidified by injecting perchloric acid (6% final
concentration) with a syringe. The liberated CO2 was
trapped in a plastic well suspended from the septa caps containing 0.4 ml of methanolic benzethonium hydroxide. After 1 h of incubation
at 37 °C, the wells were removed, and the trapped
14CO2 was measured by liquid scintillation
counting. Cells were scraped in cold phosphate-buffered saline,
pelleted by centrifugation, and resuspended in 4 ml of Folch reagent
(9). Total lipids were extracted and separated by thin layer
chromatography to measure the incorporation of labeled palmitate into
phospholipids (9). The cellular triglyceride content was measured as
described previously (9). Triglyceride recovery assessed with triolein
was 94 ± 5% (n = 4).
Statistical Analysis--
All results are expressed per mg of
protein or µg of DNA as the mean ± S.E. of the indicated number
of experiments. Statistical significance was calculated with the
Student's t test.
Glucose Down-regulates the Expression Level of PPAR
Increasing glucose from 3 to 20 mM causes a
dose-dependent down-regulation of PPAR Glucose Reduces the DNA Binding Activity of PPAR Glucose Down-regulates the mRNA Expression Level of Some Genes
Containing a PPRE Sequence--
The mRNA expression of three genes
implicated in the control of fat oxidation was measured after a 48-h
period of exposure to high glucose (Fig.
5). The genes encoding UCP2 and ACO have been documented to contain PPRE sequences in their promoters (26). By
contrast, only the muscle type CPT I gene, but not the liver-type CPT I
gene, which is expressed in the Mechanism of Glucose Regulation of PPAR Chronic Exposure of INS-1 Cells to Elevated Glucose and FFA
Markedly Alter Their Malonyl-CoA Content, Lipid Partitioning, and
Insulin Secretion--
Additional experiments are reported to link the
observed changes in the expression of PPAR
As expected from previous work (44), high glucose acutely increases the
malonyl-CoA content of INS-1 cells (Fig.
8A) and reduces fat oxidation
(Fig. 8B). Chronic oleate slightly decreases the cellular
malonyl-CoA content and increases fat oxidation. A long term exposure
to high glucose causes a 6-fold rise in malonyl-CoA and a more than
60% reduction of fat oxidation, even in cells that are subsequently
incubated at low (5 mM) glucose (Fig. 8). Qualitatively
similar observations were made in cells chronically exposed to both
elevated glucose and fatty acids, although the effects are
quantitatively less prominent, with a 2-fold rise in malonyl-CoA. This
is consistent with the fact that FFA partly antagonize the inductive
action of glucose on acetyl-CoA carboxylase, which synthesizes
malonyl-CoA (14). Finally, the results in Fig. 8 show that malonyl-CoA
is elevated by about 2.5-fold and that fat oxidation is reduced by more
than 80% in cells preexposed to both elevated glucose and oleate for 3 days and in which high glucose is present during the incubation
period.
Chronic elevated glucose and oleate alone increase the esterification
of palmitate into total lipid and phospholipids and promote TG
deposition in INS-1 cells (Fig. 9). A
similar observation was made in the combined presence of high glucose
and oleate. In addition, glucose and oleate synergize to cause TG
accumulation in INS cells (Fig. 9).
In accordance with previous work done on rat islets and INS cells (9,
13), a long term exposure of The results indicate that elevated glucose markedly down-regulates
the expression of the PPAR To date there are very few examples of genes whose expression level is
down-regulated by glucose. Glucose reduces the expression of the
phosphoenolpyruvate carboxykinase gene in hepatocytes (45). By
contrast, elevated glucose induces several glycolytic and lipogenic genes, in particular liver-type pyruvate kinase (13) and acetyl-CoA carboxylase (14), by a mechanism that requires phosphorylation of the
sugar. The mediator of the action of glucose is not known, but it might
be glucose-6-phosphate or ribulose 5-phosphate (46), an intermediate of
the pentose phosphate pathway. The results in this study indicate that
many of the characteristics of the action of glucose on the PPAR The DNA response elements mediating the action of glucose on the
PPAR The only tested agents besides glucose and mannose that reduce PPAR Islets from ZDF fa/fa rats show reduced PPAR Fatty acid esterification processes may be implicated in the regulation
of insulin secretion through the generation of lipid mediators such as
diacylglycerol (41). Thus, provided it can be verified in the in
vivo situation, a down-regulation of PPAR
-cell and the link between chronically
elevated glucose or fatty acids and
-cell decompensation in
adipogenic diabetes, we investigated whether glucose regulates
peroxisomal proliferator-activated receptor (PPAR) gene expression in
the
-cell. Islets or INS(832/13)
-cells exposed to high
glucose show a 60-80% reduction in PPAR
mRNA expression.
Oleate, either in the absence or presence of glucose, has no effect.
The action of glucose is dose-dependent in the 6-20
mM range and maximal after 6 h. Glucose also
causes quantitatively similar reductions in PPAR
protein and DNA
binding activity of this transcription factor. The effect of glucose is
blocked by the glucokinase inhibitor mannoheptulose, is partially
mimicked by 2-deoxyglucose, and is not blocked by the
3-O-methyl or the 6-deoxy analogues of the sugar that are
not phosphorylated. Chronic elevated glucose reduces the expression
levels of the PPAR target genes, uncoupling protein 2 and
acyl-CoA oxidase, which are involved in fat oxidation and lipid
detoxification. A 3-day exposure of INS-1 cells to elevated glucose
results in a permanent rise in malonyl-CoA, the inhibition of fat
oxidation, and the promotion of fatty acid esterification processes and
causes elevated insulin secretion at low glucose. The results suggest
that a reduction in PPAR
gene expression together with a rise in
malonyl-CoA plays a role in the coordinated adaptation of
-cell
glucose and lipid metabolism to hyperglycemia and may be implicated in
the mechanism of
-cell "glucolipotoxicity."
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cell decompensation and failure in
non-insulin-dependent diabetes mellitus are beginning to be
understood. What is emerging from the recent literature is that, in
addition to genetic predisposition, changes in lipid partitioning may
play an important role in the development of
-cell failure (1, 2).
Thus, triglyceride (TG) overload in the
-cell correlates with
altered glucose-induced secretion and apoptotic cell death (5). In
addition, pharmacological (6, 7) or molecular biological (8) strategies
aiming at reducing islet fat overload improve
-cell function.
Altered lipid metabolism, rather than glucose metabolism,
appears to be implicated in this so-called
-cell "lipotoxicity"
via a process that apparently does not involve a Randle cycle,
in which enhanced fat oxidation reduces glucose metabolism (9). This
view is in accordance with the observation that enhanced
-cell lipid synthesis and esterification characterize the
-cell of ZDF rats (10). Also consistent with the possibility that changes in lipid metabolism are central to the process of
-cell
"glucolipotoxicity" (1) is that ZDF rats show enhanced lipogenesis
in association with increased levels of the lipogenic enzymes
acetyl-CoA carboxylase and fatty acid synthase and the esterifying
enzyme glycerol-3-phosphate acyltransferase (10). Interestingly,
glucose causes a coordinated induction of lipogenic genes and promotes
lipid esterification and TG deposition in
(INS) cells (11).
-cell in non-insulin-dependent diabetes mellitus (1), there is much interest in defining the genes
whose expression are altered by glucose or fatty acids in islet tissue.
We know that both glucose and FFA regulate the expression level of
-cell genes encoding key regulatory enzymes in the glycolytic (12-15), lipogenic (11), and fat oxidation (16) pathways and of
the insulin gene (17, 18). However, little is known about the
action of these calorigenic nutrients on the expression of transcription factors in the
-cell or other cell types. This may
prove particularly relevant to our understanding of obesity-associated diabetes, because transcription factors are expected to translate variations in the nutritional state to late phenotypic changes. Noteworthy is the fact that to date five of the six identified maturity
onset diabetes (MODY) genes are transcription factors regulating the
insulin gene and various intermediary metabolism genes (19). Our recent
work indicates that both glucose and FFA induce the transcriptional
activation of several immediate early response genes in INS
-cells
and rat islets, in particular the transcription factors
c-fos, nur 77, and members of the jun family (20-22). Glucose also increases the expression of the IDX-1 gene (23), which encodes a key
-cell transcription factor
implicated in
-cell differentiation and the control of the insulin
gene (24); by contrast, palmitate, in the presence of elevated glucose, reduces IDX-1 expression in rat islets (25).
isoform controls many genes of fat metabolism,
in particular those implicated in mitochondrial and peroxisomal
-oxidation and fatty acid synthesis and transport as well as
uncoupling proteins (26). The function of the PPAR
isoform is poorly
understood. PPAR
has a more restricted tissue distribution than the
and
isoforms. It plays an essential role in fat cell
differentiation and lipid storage and may be a "thrifty" gene (27).
Little is known about the role of PPARs in
-cell function.
The three isoforms are expressed in purified
and INS
cells2 as well as in rat
islets (28). PPAR
mRNA expression has been reported to be
induced by high concentrations of FFA in rat islets (28).
Interestingly, the antidiabetic PPAR
ligand troglitazone prevents
diabetes in ZDF rats as well as TG deposition and
-cell lipoapoptosis both in vivo (29) and ex vivo
(6).
-cell failure in diabetes and because altered lipid
partitioning, a process controlled by PPARs, probably contributes to
this process, this study was designed to gain insight into glucose and
fatty acid regulation of PPAR
expression in the
-cell.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-mercaptoethanol. INS(832/13) cells were seeded in 60-mm tissue
culture dishes (6 × 106 cells/dish) and cultured in
complete RPMI medium. On the next day, islets and INS(832/13) cells
were preincubated for 24 h in complete culture medium containing 3 mM glucose. Finally, they were incubated in complete
culture medium at various glucose concentrations in the absence or the
presence of oleate (0.4 mM) bound to 0.5% albumin (9) for
the indicated periods of time. The experiments dealing with the
regulation of PPAR
gene expression were carried out with the new
clonal cell line INS(832/13) derived from INS-1 cells. The action of
chronic elevated oleate and glucose on
-cell metabolism and insulin
secretion was carried out with the original INS-1 cells at passages
below 85. Thus, we performed this work just prior to the
availability of the new clone INS(832/13). Albumin-bound oleate was
prepared by stirring the fatty acid Na salt at 45 °C with defatted
bovine serum albumin (BSA)(Sigma Fraction V). After adjustment of the
pH to 7.4, the solution was filtered through a 0.22-µm filter, and
the fatty acid concentration was measured using a NEFAC kit
(Wako Chemicals GmbH). For incubations longer than 24 h, the
medium was changed daily to maintain a constant concentration of fatty
acid. The final concentration of BSA in the culture medium was
0.5%.
) and 1 µl (
-actin) of the reverse transcription mixtures were amplified in a final volume of 50 µl with specific primers for
the following rat cDNAs. Amplification of rat PPAR
(28), uncoupling protein 2 (UCP2) (35), acyl-CoA oxidase (ACO) (6), and
carnitine palmitoyltransferase I (CPT I) (6) was done using the primers
and experimental conditions described in the cited references.
Amplification of rat
-actin was done using the following parameters
and primers: 92 °C for 30 s, 63 °C for 1 min, and
72 °C for 1 min during 25 cycles; 5'-GTGCCCATCTATGAGGGTTACGCG-3' (sense); 5'-GGAACCGCTCATTGCCGATAGTG-3' (antisense). The
linearity of each PCR was tested by amplification of 500 ng of total
RNA/reaction. It was linear from 20 to 45 cycles. Ten µl of the PCR
products were subjected to electrophoresis on 1.2% agarose gels
followed by Southern blotting on a zeta probe membrane. The following
specific radiolabeled probe was used for
-actin:
5'-TCATGCCATCCTGCGTCTGGACCT-3'. The probes for PPAR
(28),
UCP2 (35), ACO (6), and CPTI (6) are indicated in the cited references.
The hybridization signals were quantitated by scanning the autoradiograms.
70 °C. The protein concentration of
the nuclear extracts was then measured. The oligonucleotides used to
assess the DNA binding activities of PPAR
and adenovirus-5 major
late transcription factor (MLTF) by electrophoretic mobility shift
assays were purchased from Alpha-DNA (Montreal, Quebec, Canada).
A 20-mer sense oligonucleotide (5'-CGTCTGCCCTTTCCCCCTCT-3') and
a 20-mer antisense oligonucleotide (5'-GAGAAGAGGGGGAAAGGGCA-3')
containing the PPAR responsive element (PPRE) of the lipoprotein lipase
promoter were annealed and used to assess PPAR
binding activity. A
28-mer sense oligonucleotide (5'-TAGGTGTAGGCCACGTGACCGGGTGTTC-3') (and
its corresponding antisense) described to bind MLTF (37) was
used to assess MLTF DNA binding activity. The conditions used for the
electrophoretic mobility shift assays were as described (36). Briefly,
5 µg of nuclear extracts were incubated with a radiolabeled probe
(20,000 cpm per sample) for 15 min in 15 µl of binding buffer (25 mM Hepes, 10% glycerol, 50 mM NaCl, 0.05%
Nonidet P-40, and 1 mM dithiothreitol, pH 7.5) in the
presence or absence of 2 µl of anti-PPAR
, anti-PPAR
(kindly
provided by Dr. W. Wahli, University of Lausanne, Lausanne, Switzerland), and anti-PPAR
antisera (Calbiochem). A 100-fold molar
excess of cold probe was used to assess the specificity of the binding
of nuclear proteins. Samples were analyzed on 4% nondenaturating
polyacrylamide Tris-glycine gels (37).
was detected using a rabbit antibody raised against this protein
(dilution 1:500) and a horseradish peroxidase-conjugated goat
anti-rabbit immunoglobulin antibody (dilution 1:8000). Detection was
carried out with the enhanced chemiluminescence detection technique.
70 °C. Malonyl-CoA was assayed with a
radioactive method using fatty acid synthase (38). For insulin
secretion determinations, INS-1 cells were plated (105
cells/well) into 24-well plates. They were cultured and incubated as
described above for malonyl-CoA measurements. The insulin concentration in the medium was determined by radioimmunoassay using rat insulin as a
standard (9). Total cellular insulin content was measured after
acid-ethanol (1.5% HCl, 75% ethanol) extraction.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
mRNA in
Insulin-secreting Cells--
Total RNA was isolated from batches of 50 islets, and the expression level of the PPAR
transcript was measured
by a semiquantitative reverse transcriptase-PCR technique. The
quantitation of PPAR
isoform is expressed as the ratio of PPAR
to
actin mRNA. Fig. 1 shows that the
expression of the PPAR
mRNA species is down-regulated by
elevated glucose in rat islets. Glucose also decreases the expression
of the PPAR
transcript in the highly glucose-responsive clonal
-cell line INS(832/13) (32) (Fig. 1), although the effect is
slightly more prominent (80% reduction) than in rat islets. Oleate, in
contrast to glucose, does not alter the mRNA expression level of
PPAR
in either rat islets or INS(832/13) cells (Fig. 1). In
addition, the action of glucose is similar in the absence or presence
of oleate. A previous report documented that a FFA mixture of
palmitate/oleate (1:2) (2 mM; concentration of albumin unknown) induced the PPAR
transcript in rat islets (28). We measured
PPAR
expression in INS(832/13) cells following a 72-h incubation
period in the presence of a 0.5 or 2 mM palmitate/oleate (1:2) mixture bound to 0.5 and 2% albumin, respectively. The
palmitate/oleate mixture did not change the abundance of the PPAR
transcript (data not shown). The reason for the dichotomy between the
present work and this previous study remains to be explained. Perhaps
the albumin concentration is important in this respect. The results
indicate that INS(832/13) cells can serve as a model system to further characterize and understand the mechanism whereby glucose modulates the
expression of the PPAR
gene, which coordinates the expression of
several metabolic genes in the fat oxidation pathway (26).

View larger version (13K):
[in a new window]
Fig. 1.
Effect of glucose and oleate, singly or
combined, on the expression level of PPAR
mRNA in rat islets and INS(832/13) cells. Quantitation
of the expression level of PPAR
mRNA after a 24-h culture period
of isolated rat islets and INS(832/13) cells at 3 or 20 mM
glucose, with or without 0.4 mM oleate. The results are
expressed as the mean ± S.E. of three experiments. *,
p < 0.01.
mRNA with a
threshold concentration of 6 mM and 70% reduction at 20 mM glucose (Fig.
2A). The inhibitory action of
glucose is rapid because it occurs with a lag time of about 2 h
and is maximal at 6 h (Fig. 2B). The same reduction observed in PPAR
mRNA expression at 6 h was
observed after a 24-h (Fig. 2B) or 48-h (data not shown)
incubation period.

View larger version (28K):
[in a new window]
Fig. 2.
Glucose down-regulates
PPAR
mRNA expression in INS(832/13) cells
in a dose- and time-dependent manner. A,
following a 24-h preincubation period at 3 mM glucose,
cells were incubated for 24 h at different glucose concentrations.
B, cells were incubated at 20 mM glucose for
different time periods. Mean ± S.E. of three experiments.
and the
Expression of the PPAR
Protein--
The DNA binding activity of
PPAR
for its cis-regulatory element in the lipoprotein
lipase promoter was tested by an electrophoretic mobility shift
assay using nuclear extracts of low (3 mM) and high
(20 mM) glucose-treated cells. Fig.
3A shows the results of a
representative experiment, and Fig. 3B shows the
quantitation of six separate experiments. Glucose decreases the DNA
binding activity of PPAR
for its PPRE cis-element by 80%
(Fig. 3A, lane 1 versus lane
4). The higher intensity of the low molecular weight band in
lane 2 compared with that in lane 1 was not
observed reproducibly. To determine that the shifted band is due to
PPAR
binding to the DNA probe, supershift assays were also performed
with anti-PPAR
, anti-PPAR
, and anti-PPAR
antibodies.
Lane 2 shows the complete disappearance of the shifted band
in the presence of PPAR
antiserum. In blots other than the one shown
in Fig. 3, the labeled probe was not supershifted with specific
antibodies against PPAR
or PPAR
(data not shown). This
demonstrates that the retardation of the migration of the PPRE probe on
the gel is due to its binding to PPAR
. To assess the integrity of
the samples and further test the specificity of the glucose effect, the
MLTF cis-element was used as a control in the
electrophoretic mobility shift assay. MLTF is a ubiquitously
distributed DNA-binding protein that is insensitive to changes
in glucose concentration in rat islets (37). As shown in Fig.
3A, the DNA binding activity of MLTF is not changed
at high glucose (lane 6 versus lane
7), which attests to the specificity of the action of the sugar on
PPAR
. The reduced DNA binding activity of PPAR
at high glucose is
probably due to a decreased expression of the PPAR
protein. Indeed
Fig. 4 shows that chronic exposure of
INS(832/13) cells to elevated glucose reduces the amount of the PPAR
protein by about 75% as assessed by the Western blot technique.

View larger version (30K):
[in a new window]
Fig. 3.
Glucose decreases the DNA binding activity of
PPAR
. A, representative DNA
binding activities of PPAR
(lanes 1-5) and MLTF
(lanes 6-9) are shown. Electrophoretic mobility shift
assays were done with nuclear extracts of INS(832/13) cells
cultured for 2 days at 3 mM (lanes 1 and
6) or 20 mM (lanes 4 and
7) glucose. The specificity of PPAR
DNA binding was
assessed by adding a PPAR
antibody (lane 2) to the same
nuclear extract that was used for lane 1. Competition
experiments with a 100-fold excess of cold probes (lanes 3 and 8) were done with the same extracts that were used in
lanes 1 and 6, respectively. As negative
controls, no nuclear extracts were added in lanes 5 and
9 with each probe. B, quantitation of the DNA
binding activities of PPAR
and MLTF at 3 mM
(G3) or 20 mM (G20) glucose.
Mean ± S.E. of six experiments. *, p < 0.0002.

View larger version (20K):
[in a new window]
Fig. 4.
Glucose down-regulates the expression of the
PPAR
protein. INS(832/13) cells were
incubated for 48 h at 3 mM (G3) or 20 mM (G20) glucose. The PPAR
protein was
measured by Western blot analysis. Mean ± S.E. of three
experiments. *, p < 0.05.
-cell (40), was shown to
contain a PPRE regulatory sequence (54). UCP2 and ACO mRNA levels
are reduced by 70 and 50%, respectively in cells chronically exposed
to high glucose (Fig. 5). By contrast, and in agreement with previous
work (16), the sugar has no effect on liver-type CPT I mRNA
expression. The PPAR
agonist clofibrate does not increase CPT I
mRNA in INS cells (16), and fatty acids and elevated
glucose can still induce the islet CPT I gene in
PPAR
/
mice.3 Therefore, the
observation of a lack of an associated decreased expression of the CPT
I transcript when PPAR
is down-regulated by glucose is consistent
with the view that PPAR
is not implicated in the control of the
liver-type CPT I gene.

View larger version (13K):
[in a new window]
Fig. 5.
Glucose down-regulates the expression level
of some genes containing identified PPAR responsive elements.
INS(832/13) cells were incubated for 48 h at 3 mM
(G3) or 20 mM (G20) glucose. The
different transcripts were measured by reverse transcriptase-PCR
analysis followed by Southern blot hybridization. Mean ± S.E. of
three experiments. *, p < 0.05.
Gene
Expression--
Two sets of experiments were performed to gain insight
into the mode of action of glucose on the PPAR
gene. First, we
tested the action of protein and RNA synthesis inhibitors.
Cycloheximide does not alter the action of glucose (Fig.
6A). This indicates that the
action of glucose occurs in the absence of de novo protein synthesis. The stability of PPAR
mRNA is the same at low (3 mM) and high (20 mM) glucose in the presence of
actinomycin D, which inhibits RNA synthesis (Fig. 6B). This
indirectly suggests that the action of glucose occurs at the
transcriptional level. Secondly, we tested several glucose analogues,
nutrient stimuli, and pharmacological agents (Fig.
7). Mannose, an epimer of glucose that is
well metabolized in the
-cell (41), reproduces the action of
glucose. The effect of glucose is suppressed by the glucokinase (GK)
inhibitor mannoheptulose. 6-deoxyglucose and
3-O-methylglucose, two glucose analogues that rapidly enter
the
-cell via Glut2 but are not phosphorylated by GK (39), have no
effect. 2-deoxyglucose, which is phosphorylated by GK, reduces PPAR
expression, although less effectively than glucose. Pyruvate or
glutamine plus leucine, which promote insulin secretion in INS cells
(41), does not alter the mRNA expression levels of PPAR
.
Elevated K+, phorbol 12-myristate 13-acetate, and
forskolin, which are good secretagogues and activate the
Ca2+-, protein kinase C-, and cAMP-signaling systems (42),
respectively, were tested. A depolarization of the plasma membrane with
high K+ and an increase of intracellular cAMP levels
reduces PPAR
by about 40%. Activation of the protein kinase C
pathway with phorbol 12-myristate 13-acetate has no effect. To evaluate
whether the effect of glucose occurs indirectly via an autocrine action
of insulin, two inhibitors of insulin secretion were used. Epinephrine, which suppresses insulin secretion at a late step in the exocytic process (43), and nifedipine, which curtails secretion by impairing Ca2+ influx via L-type Ca2+ channels (42), have
no effect. Likewise, exogenous insulin does not alter PPAR
mRNA
expression. This series of experiments rules out an autocrine action of
insulin on PPAR
expression.

View larger version (11K):
[in a new window]
Fig. 6.
The regulation of PPAR
gene expression by glucose occurs in the absence of de
novo protein synthesis, and glucose does not affect the
stability of the PPAR
transcript.
A, after a 24-h preincubation at 3 mM glucose,
INS(832/13) cells were incubated for 24 h in the presence of 3 mM (G3) or 20 mM (G20)
glucose, with or without 10 µg/ml cycloheximide (Chx).
B, cells were incubated at 3 or 20 mM glucose
for different periods of time in the presence of 5 µg/ml actinomycin
D. Mean ± S.E. of three experiments. *, p < 0.005

View larger version (29K):
[in a new window]
Fig. 7.
Effect of various glucose analogs, nutrient
secretagogues, and test substances on PPAR
mRNA expression in INS(832/13) cells. Following a 24-h
preincubation period at 3 mM glucose, cells were incubated
for 24 h in fresh RPMI medium containing the following test
substances: 3 mM glucose (G3), 20 mM
glucose (G20), 30 mM mannose, 20 mM
glucose + 30 mM mannoheptulose (G20 + MH), 20 mM 2-deoxyglucose (2-DOG), 20 mM
6-deoxyglucose (6-DOG), 20 mM
3-O-methylglucose (3-OMG), 15 mM
pyruvate, 10 µM forskolin, 30 mM KCl, 0.1 µM phorbol 12-myristate 13-acetate (PMA), 10 mM glutamine + 10 mM leucine (Gln + Leu), 20 mM glucose + 10 µM epinephrine
(G20 + Epi), 20 mM glucose + 100 nM
nifedipine (G20 + Nif), and 10 nM
insulin. Mean ± S.E. of 3-6 experiments. **,
p < 0.0005; *, p < 0.05.
and fat oxidation genes
to
-cell lipid metabolism and insulin secretion. This series of
experiments was carried out in the original INS-1 cells just prior to
when the new INS(832/13) clone was made available.

View larger version (15K):
[in a new window]
Fig. 8.
Effect of chronic high glucose and oleate,
singly or combined, on fatty acid oxidation and the malonyl-CoA content
of INS-1 cells. Cells were cultured at 5 mM
(G5) or 25 mM (G25), with or without
0.4 mM oleate (Ol.) for 3 days, and incubated
for 30 min (malonyl-CoA determination) or for 1 h (palmitate
oxidation measurements) at 5 or 25 mM glucose. Mean ± S.E. of 3-4 experiments. **, p < 0.01; *,
p < 0.05.

View larger version (15K):
[in a new window]
Fig. 9.
Effect of chronic high glucose and oleate,
singly or combined, on the esterification of palmitate and the
triglyceride content of INS-1 cells. Cells were cultured at 5 mM (G5) or 25 mM (G25),
with or without 0.4 mM oleate for 3 days and subsequently
incubated for 1 h with the corresponding concentrations of glucose
and oleate. Upper panel, triglyceride content.
Middle and lower panels, incorporation of
palmitate into total lipids and phospholipids (PL),
respectively. **, p < 0.05; *, p < 0.01.
-cells to high glucose or oleate alone
results in high basal secretion at 5 mM glucose and a lack
of insulin release in response to a further rise in glucose (Fig.
10). Interestingly, the actions of
chronic elevated glucose and oleate are additive, with a very high
basal insulin secretion rate and also a lack of secretory response to
the sugar at concentrations between 5 and 25 mM (Fig.
10).

View larger version (21K):
[in a new window]
Fig. 10.
Effect of chronic high glucose and oleate,
singly or combined, on insulin secretion in INS-1 cells. Cells
were cultured for 3 days at 5 mM (G5) or 25 mM (G25) glucose in the absence or presence of
0.4 mM oleate bound to BSA (0.5%). Cells were subsequently
incubated for 30 min in KRBB-Hepes medium at 5 or 25 mM
glucose. The insulin released is expressed as a percent of the total
cellular insulin content. The insulin contents of cells cultured at 5 mM glucose in the absence or presence of oleate
(Ol.) were 1.86 ± 0.01 and 1.72 ± 0.01 µg/mg
protein, respectively. The values for cells cultured at 25 mM glucose in the absence or presence of oleate were
1.07 ± 0.01 and 0.76 ± µg/mg protein, respectively.
Mean ± S.E. of 12 wells in three separate experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
gene in the
-cell. The action of
glucose on PPAR
mRNA expression occurs in less than 2 h and does not require de novo protein synthesis. The rapidity of
the effect and the absence of a requirement for protein synthesis indicate that the PPAR
gene behaves as an early response gene in
INS(832/13) cells. Therefore, this transcription factor could play an
important role in the coordinated control of glucose and lipid
metabolism in the
-cell in response to hyperglycemia.
gene (e.g. the specificity for sugars that are
phosphorylated by GK, the absence of an effect of other calorigenic
nutrient secretagogues) are similar to those previously observed for
the glucose induction of the liver-type pyruvate kinase (47),
acetyl-CoA carboxylase (14), and fatty acid synthase (48) genes. This
suggests that a similar metabolic intermediate, possibly
glucose-6-phosphate, mediates the action of glucose by up- or
down-regulating the expression of some genes. We do not favor the view
that the pentose phosphate intermediate ribulose 5-phosphate is
implicated in the action of glucose on gene expression, because glucose
rapidly reduces the flux of glucose carbon through this pathway in the
-cell (49).
gene remain to be defined. Interestingly, two sequences similar
to the consensus glucose responsive element (CACGTG) found in many
glucose responsive genes (50, 51) are present in the PPAR
promoter.
These sequences correspond to positions
867/
862 (CACCTG) and
130/
125 (CACGCG). It will be of interest to determine whether these
putative glucose response elements are implicated in the
down-regulation of the PPAR
gene by glucose. This will reveal
whether the same consensus response element mediates both the induction
and the repression of some genes by carbohydrates.
mRNA expression are forskolin and high K+, although
both are clearly less effective than glucose. Whether cAMP directly
regulates PPAR
expression should be considered. However, elevated
cAMP might indirectly regulate PPAR
expression via intracellular
glucose production through glycogen breakdown, because INS cells in
culture contain appreciable amounts of glycogen (13). The action of
glucose is unlikely to be modulated via cAMP signaling because glucose
does not modify cAMP levels in INS cells (21). Elevated KCl slightly
reduces PPAR
mRNA expression. Nonetheless, the Ca2+
signaling system is unlikely to be implicated in the action of glucose
because the Ca2+ channel antagonist nifedipine, which
suppresses the glucose-induced Ca2+ rise (42), does not
alter the action of glucose. In addition, pyruvate and Gln plus Leu,
which promote Ca2+ influx in INS cells, are ineffective.
mRNA expression (28) in association with reduced fat oxidation and
increased lipid esterification processes (10). As far as lipid
metabolism gene expression is concerned, ZDF islets exhibit increased
expression of the esterifying enzyme glycerol-3-phosphate
acyltransferase (10) and reduced expression of the UCP2 transcript
(35), whereas the liver-type CPT I mRNA level is unaltered (28). It
is interesting to note that similar changes are observed in INS cells
chronically exposed to elevated glucose. Thus, high glucose causes a
sustained increased in malonyl-CoA, reduced fat oxidation, and
increased phospholipids and TG synthesis. In addition, the sugar
reduces the expression of the PPAR
, ACO, and UCP2 genes, with no
change in CPT I mRNA level. Because the ACO (52) and UCP2 (53)
genes contain PPRE in their promoters and are regulated by PPAR
(26), it is tempting to suggest that the glucose-induced
down-regulation of PPAR
in the
-cell might be implicated in the
redirection of lipid metabolism from fat oxidation to esterification
during hyperglycemia (1). We will directly evaluate this hypothesis by
changing the expression of PPAR
in the
-cell using the tools of
molecular biology.
expression by
episodes of postprandial glucose elevations might play a role in the
-cell compensation phase in the development of adipogenic diabetes
(see Fig. 11). Consistent with this
view, chronic (3 days) high glucose and oleate have an additive effect in causing high basal insulin secretion in INS cells. However, at later
stages in the progression toward diabetes, with increasing insulin
resistance, long episodes of postprandial hyperglycemia, and elevated
FFA, the glucose-induced reduction of PPAR
expression might be
implicated in the
-cell demise by virtue of its key role in lipid
partitioning. Indeed, the three known pathways of lipid detoxification
implicating fat oxidation are mitochondrial
-oxidation, which is
limited by CPT I activity (40), peroxisomal fatty acid
oxidation, where ACO is the limiting enzyme (26), and uncoupled fat
oxidation, which may involve UCP2 (55, 56). Thus, in response to
chronic elevations in glucose the three fat oxidation pathways would be
inhibited by 1) the chronically elevated malonyl-CoA, which suppresses
CPT I activity, and 2) the reduction of the two remaining pathways
mediated by glucose-induced decreases in ACO and UCP2 expression caused
by the decrease in PPAR
. Consistent with this view, malonyl-CoA is
elevated, fat oxidation is almost totally suppressed, and lipid
esterification processes are markely increased following long term
exposure of INS cells to both elevated glucose and oleate. With respect
to this new working hypothesis implicating both reduced PPAR
expression and a sustained rise in malonyl-CoA in the mechanism of
-cell glucolipotoxicity (see Fig. 11), it is interesting to
note that the PPAR
ligand troglitazone (at very high concentrations
that may cause PPAR
activation) reverses the secretory and lipid
metabolism alterations of the
-cell in ZDF rats (6). In addition,
treatments of yellow KK mice with BM17.0744, a new PPAR
agonist, results in an amelioration of the diabetic status and
dyslipidemia (57).

View larger version (23K):
[in a new window]
Fig. 11.
Model implicating PPAR
and malonyl-CoA in the pancreatic
-cell
adaptation to chronic hyperglycemia and the mechanism of
-cell glucolipotoxicity. In the absence of
hyperglycemia, fatty acids, even when elevated as occurs during the
early prediabetic phase of adipogenic diabetes, are oxidized
(detoxification) and do not accumulate to a large extent in the
-cell. The three fatty acid oxidation pathways are
mitochondrial
-oxidation, in which CPT I is limiting, peroxisomal
-oxidation, in which ACO is limiting, and uncoupled mitochondrial
oxidation, which involves UCP2. With hyperglycemia (postprandial or
chronic) the three pathways of fat oxidation are reduced because of 1)
a sustained elevation in malonyl-CoA that inhibits CPTI, and 2) a
reduction in PPAR
expression that down-regulates ACO and UCP2. The
glucose-induced suppression of fat oxidation causes fatty acyl-CoA
(FA-CoA) accumulation in the cytoplasm and alters
-cell
lipid partitioning by deriving fatty acyl-CoA from oxidation towards
esterification. This results in increased phospholipid and
diacylglycerol synthesis as well as triglyceride deposition.
This process may initially contribute to
-cell compensation
of insulin resistance via the accelerated production of lipid mediators
such as the protein kinase C activator diacylglycerol that would
increase insulin secretion. However, with time, the chronic suppression
of fat oxidation will result in massive fat deposition in the
-cell,
thus causing the
-cell demise (decompensation phase) and overt
diabetes. G3P, glycerol 3-phosphate; DAG,
diacylglycerol; PL, phospholipid;
-ox.,
-oxidation; detox.,
detoxification; IRI, immunoreactive insulin.
In conclusion, glucose at concentrations in the range of 3-20
mM rapidly down-regulates the expression of the PPAR
gene by a mechanism that requires phosphorylation of the sugar by GK. The action of glucose does not require de novo protein
synthesis and probably occurs at the transcriptional level. It is
suggested that a reduction of PPAR
gene expression together with
chronic elevated malonyl-CoA plays a role in the coordinated adaptation of the
-cell glucose and lipid metabolism to hyperglycemia and may
be implicated in the mechanism of
-cell glucolipotoxicity. The
synergistic accumulation of TG in the
-cell in the combined presence
of elevated glucose and FFA is consistent with this view, as
illustrated in Fig. 11.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. B. Thorens and Dr. S. Gremlich for helpful discussions and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the Medical Research Council of Canada, the Canadian Diabetes Association, and the Juvenile Diabetes Foundation International (to M. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported last year by a post-doctoral fellowship from the Juvenile Diabetes Foundation (3-1999-32) and presently supported by a postdoctoral fellowship from the Swiss National Science Foundation (823A-56687).
** A Medical Research Council of Canada Scientist. To whom correspondence should be addressed: CR-CHUM, Pavillon de Sève, 4e, 1560 Sherbrooke Est, Montreal, PQ, H2L 4M1, Canada. Tel.: 514 281 6000 (ext. 6811); Fax.: 514 896 4884; E-mail: marc.prentki@umontreal.ca.
Published, JBC Papers in Press, August 30, 2000, DOI 10.1074/jbc.M006001200
2 N. Voilley, F. Schuit, and M. Prentki, unpublished data.
3 S. Gremlich and W. Wahli, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ZDF, Zucker Diabetic Fatty; TG, triglyceride; FFA, free fatty acid; PPAR, peroxisome proliferator-activated receptor; BSA, bovine serum albumin; PCR, polymerase chain reaction; UCP2, uncoupling protein 2; ACO, acyl-CoA oxidase; CPT I, carnitine palmitoyltransferase I; MLTF, major late transcription factor; PPRE, PPAR responsive element; KRBB, Krebs-Ringer bicarbonate buffer; GK, glucokinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Prentki, M., and Corkey, B. E. (1996) Diabetes 45, 273-283 |
| 2. | Unger, R. H. (1995) Diabetes 44, 863-870 |
| 3. | McGarry, J. D. (1992) Science 258, 766-770 |
| 4. | Ohneda, M., Inman, L. R., and Unger, R. H. (1995) Diabetologia 38, 173-179 |
| 5. | Shimabukuro, M., Zhou, Y. T., Levi, M., and Unger, R. H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2498-2502 |
| 6. | Shimabukuro, M., Zhou, Y. T., Lee, Y., and Unger, R. H. (1998) J. Biol. Chem. 273, 3547-3550 |
| 7. | Shimabukuro, M., Koyama, K., Chen, G., Wang, M. Y., Trieu, F., Lee, Y., Newgard, C. B., and Unger, R. H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4637-4641 |
| 8. | Chen, G., Koyama, K., Yuan, X., Lee, Y., Zhou, Y.-T., O'Doherty, R. M., Newgard, C. B., and Unger, R. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14795-14799 |
| 9. | Segall, L., Lameloise, N., Assimacopoulos-Jeannet, F., Roche, E., Corkey, P., Thumelin, S., Corkey, B. E., and Prentki, M. (1999) Am. J. Physiol. 277, E521-E528 |
| 10. | Lee, Y., Hirose, H., Zhou, Y. T., Esser, V., McGarry, J. D., and Unger, R. H. (1997) Diabetes 46, 408-413 |
| 11. | Roche, E., Farfari, S., Witters, L. A., Assimacopoulos-Jeannet, F., Thumelin, S., Brun, T., Corkey, B. E., Saha, A. K., and Prentki, M. (1998) Diabetes 47, 1086-1094 |
| 12. | Brun, T., Assimacopoulos-Jeannet, F., Corkey, B. E., and Prentki, M. (1997) Diabetes 46, 393-400 |
| 13. | Roche, E., Assimacopoulos-Jeannet, F., Witters, L. A., Perruchoud, B., Yaney, G., Corkey, B., Asfari, M., and Prentki, M. (1997) J. Biol. Chem. 272, 3091-3098 |
| 14. | Brun, T., Roche, E., Kim, K. H., and Prentki, M. (1993) J. Biol. Chem. 268, 18905-18911 |
| 15. | Jonas, J. C., Sharma, A., Hasenkamp, W., Ilkova, H., Patane, G., Laybutt, R., Bonner-Weir, S., and Weir, G. C. (1999) J. Biol. Chem. 274, 14112-14121 |
| 16. | Assimacopoulos-Jeannet, F., Thumelin, S., Roche, E., Esser, V., McGarry, J. D., and Prentki, M. (1997) J. Biol. Chem. 272, 1659-1664 |
| 17. | Bollheimer, L. C., Skelly, R. H., Chester, M. W., McGarry, J. D., and Rhodes, C. J. (1998) J. Clin. Invest. 101, 1094-1101 |
| 18. | German, M. S., Moss, L. G., and Rutter, W. J. (1990) J. Biol. Chem. 265, 22063-22066 |
| 19. | Velho, G., and Froguel, P. (1998) Eur. J. Endocrinol. 138, 233-239 |
| 20. | Roche, E., Buteau, J., Aniento, I., Reig, J. A., Soria, B., and Prentki, M. (1999) Diabetes 48, 2007-2014 |
| 21. | Susini, S., Roche, E., Prentki, M., and Schlegel, W. (1998) FASEB J. 12, 1173-1182 |
| 22. | Susini, S., Van, H. G., Li, S., Prentki, M., and Schlegel, W. (2000) FASEB J. 14, 128-136 |
| 23. | Buteau, J., Roduit, R., Susini, S., and Prentki, M. (1999) Diabetologia 42, 856-864 |
| 24. | Ohlsson, H., Karlsson, K., and Edlund, T. (1997) EMBO J. 12, 4251-4259 |
| 25. | Gremlich, S., Bonny, C., Waeber, G., and Thorens, B. (1997) J. Biol. Chem. 272, 30261-30269 |
| 26. | Desvergne, B., and Wahli, W. (1999) Endocr. Rev. 20, 649-688 |
| 27. | Auwerx, J. (1999) Diabetologia 42, 1033-1049 |
| 28. | Zhou, Y. T., Shimabukuro, M., Wang, M. Y., Lee, Y., Higa, M., Milburn, J. L., Newgard, C. B., and Unger, R. H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8898-8903 |
| 29. | Higa, M., Zhou, Y. T., Ravazzola, M., Baetens, D., Orci, L., and Unger, R. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11513-11518 |
| 30. | Gotoh, M., Maki, T., Satomi, S., Porter, J., Bonner-Weir, S., O'Hara, C. J., and Monaco, A. P. (1987) Transplantation 43, 725-730 |
| 31. | Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A., and Wollheim, C. B. (1992) Endocrinology 130, 167-178 |
| 32. | Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., and Newgard, C. B. (2000) Diabetes 49, 424-430 |
| 33. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 |
| 34. | Witsell, A. L., and Schook, L. B. (1990) Bio/Technology 9, 318-322 |
| 35. | Shimabukuro, M., Zhou, Y. T., Lee, Y., and Unger, R. H. (1997) Biochem. Cell Biol. 237, 359-361 |
| 36. | Bonny, C., Thompson, N., Nicod, P., and Waeber, G. (1995) Mol. Endocrinol. 9, 1413-1426 |
| 37. | Sharma, A., Olson, L. K., Robertson, R. P., and Stein, R. (1995) Mol. Endocrinol. 9, 1127-1134 |
| 38. | McGarry, J. D., and Foster, D. W. (1976) J. Lipid Res. 17, 277-281 |
| 39. | Thorens, B., Sarkar, H. K., Kaback, H. R., and Lodish, H. F. (1988) Cell 55, 281-290 |
| 40. | McGarry, J. D., and Dobbins, R. L. (1999) Diabetologia 42, 128-138 |
| 41. | Prentki, M. (1996) Eur. J. Endocrinol. 134, 272-286 |
| 42. | Prentki, M., and Matschinsky, F. M. (1987) Physiol. Rev. 67, 1185-1248 |
| 43. | Sharp, G. W. (1996) Am. J. Physiol. 271, C1781-C1799 |
| 44. | Prentki, M., Vischer, S., Glennon, M. C., Regazzi, R., Deeney, J. T., and Corkey, B. E. (1992) J. Biol. Chem. 267, 5802-5810 |
| 45. | Cournarie, F., Azzout-Marniche, D., Foretz, M., Guichard, C., Ferre, P., and Foufelle, F. (1999) FEBS Lett. 460, 527-532 |
| 46. | Doiron, B., Cuif, M. H., Chen, R., and Kahn, A. (1996) J. Biol. Chem. 271, 5321-5324 |
| 47. | Marie, S., Diaz-Guerra, M. J., Miquerol, L., Kahn, A., and Iynedjian, P. B. (1993) J. Biol. Chem. 268, 23881-23890 |
| 48. | Foufelle, F., Gouhot, B., Pegorier, J. P., Perdereau, D., Girard, J., and Ferre, P. (1992) J. Biol. Chem. 267, 20543-20546 |
| 49. | Schuit, F., De Vos, A., Farfari, S., Moens, K., Pipeleers, D., Brun, T., and Prentki, M. (1997) J. Biol. Chem. 272, 18572-18579 |
| 50. | Foufelle, F., Girard, J., and Ferre, P. (1998) Curr. Opin. Clin. Nutr. Metab. Care 1, 323-328 |
| 51. | Towle, H. C., Kaytor, E. N., and Shih, H. M. (1997) Annu. Rev. Nutr. 17, 405-433 |
| 52. | Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., and Green, S. (1992) EMBO J. 11, 433-439 |
| 53. | Rieusset, J., Auwerx, J., and Vidal, H. (1999) Biochem. Cell Biol. 265, 265-271 |
| 54. | Brandt, J. M., Djouadi, F., and Kelly, D. P. (1998) J. Biol. Chem. 273, 23786-23792 |
| 55. | Ricquier, D., and Bouillaud, F. (2000) Biochem. J. 345, 161-179 |
| 56. | Boss, O., Hagen, T., and Lowell, B. B. (2000) Diabetes 49, 143-156 |
| 57. | Meyer, K., Volkl, A., Endele, R., Kuhnle, H. F., and Pill, J. (1999) Arch. Toxicol. 73, 440-450 |